arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Vistagen Therapeutics, Inc.

VTGN
$0.29 ▲ +0.01 (+3.20%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
77 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vistagen Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -47.1%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

77-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$303.00K
↑ +29.5%
Net Income Profit after all expenses
$-16.27M
↓ -19.4%
Operating Margin Operating profit as % of sales
-211.0%
↑ +34.4%
FCF / Share Free cash flow per share
$-0.42
↓ -8.5%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
2
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 28 years · 77 quarters